Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Boehringer Ingelheim
Covington
Novartis
Teva
McKinsey
Express Scripts
Daiichi Sankyo
Julphar
UBS

Generated: October 17, 2017

DrugPatentWatch Database Preview

Pf Prism Company Profile

« Back to Dashboard

What is the competitive landscape for PF PRISM, and what generic alternatives to PF PRISM drugs are available?

PF PRISM has fourteen approved drugs.

There are forty US patents protecting PF PRISM drugs and there have been two Paragraph IV challenges on PF PRISM drugs in the past three years.

There are eight hundred and twenty-seven patent family members on PF PRISM drugs in seventy-six countries and sixty-three supplementary protection certificates in fifteen countries.

Summary for Applicant: Pf Prism

International Patents:827
US Patents:40
Tradenames:10
Ingredients:10
NDAs:14
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
XALKORI
crizotinib
CAPSULE;ORAL202570-002Aug 26, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-001May 24, 2002ABRXYesNo► Subscribe► Subscribe► Subscribe
Pf Prism Cv
XELJANZ
tofacitinib citrate
TABLET;ORAL203214-001Nov 6, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-001Aug 25, 2000ABRXYesNo► Subscribe► SubscribeY► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-005Dec 30, 2004RXYesNo► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
TYGACIL
tigecycline
POWDER;IV (INFUSION)021821-001Jun 15, 2005APRXYesYes► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-002Sep 4, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-002Sep 4, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pf Prism Cv
XALKORI
crizotinib
CAPSULE;ORAL202570-001Aug 26, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-006Dec 30, 2004RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pf Prism

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv
VFEND
voriconazole
FOR SUSPENSION;ORAL021630-001Dec 19, 2003► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
SOLUTION;ORAL021083-001Sep 15, 1999► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-003Feb 23, 2004► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-001May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
TABLET;ORAL021266-002May 24, 2002► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
SOLUTION;ORAL021083-001Sep 15, 1999► Subscribe► Subscribe
Pf Prism Cv
VFEND
voriconazole
FOR SUSPENSION;ORAL021630-001Dec 19, 2003► Subscribe► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-002Dec 30, 2004► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-001Aug 25, 2000► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-002Aug 22, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PF PRISM drugs

Drugname Dosage Strength Tradename Submissiondate
tofacitinib
Tablets5 mg
XELJANZ 
11/7/2016
bosutinib
Tablets100mg and 500mg
BOSULIF
9/6/2016
temsirolimus
Injection25 mg/mL, 1.8 mL vial
TORISEL
5/25/2011
voriconazole
Oral Suspension40 mg/mL
VFEND
10/8/2010
sirolimus
Tablets0.5 mg
RAPAMUNE
8/25/2010
pregabalin
Oral Solution20 mg/mL
LYRICA
5/19/2010
sirolimus
Tablets1 mg and 2 mg
RAPAMUNE
12/17/2009
tigecycline
For Injection50 mg per vial
TYGACIL
6/15/2009
pregabalin
Capsules25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg
LYRICA
12/30/2008
voriconazole
For Injection200 mg/vial
VFEND
9/12/2008
voriconazole
Tablets50 mg and 200 mg
VFEND
4/14/2008

Non-Orange Book Patents for Pf Prism

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,684,189 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,525,096 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,359,169 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,291,526 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,884,890 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use► Subscribe
7,108,865Controlled-release dosage forms of azithromycin► Subscribe
8,445,496Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-pipera- zinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same► Subscribe
6,028,214 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
7,601,727Pyrrolo[2,3-d]pyrimidine compounds► Subscribe
6,891,044 Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pf Prism Drugs

Country Document Number Estimated Expiration
New Zealand541861► Subscribe
Serbia51362► Subscribe
Japan3856816► Subscribe
Germany602004016444► Subscribe
Denmark380688► Subscribe
European Patent Office1666481► Subscribe
Jordan2319► Subscribe
TaiwanI358406► Subscribe
Slovenia1786785► Subscribe
South Africa9706562► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pf Prism Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
06/030Ireland► SubscribePRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424
C/GB04/034United Kingdom► SubscribePRODUCT NAME: PREGABALIN (S-(+)-4-AMINO-3(2-METHYLPROPYL)BUTANOIC ACID) OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACTIVE SALT.; REGISTERED: UK EU/1/04/279/001 20040706; UK EU/1/04/279/002 20040706; UK EU/1/04/279/003 20040706; UK EU/1/04/279/004 20040706; UK EU/1/04/279/005 20040706; UK EU/1/04/279/006 20040706; UK EU/1/04/279/025 20040706; UK EU/1/04/279/019 20040706; UK EU/1/04/279/020 20040706; UK EU/1/04/279/021 20040706; UK EU/1/04/279/022 20040706; UK EU/1/04/279/023 20040706; UK EU/1/04/279/024 20040706; UK EU/1/04/279/013 20040706; UK EU/1/04/279/014 20040706; UK EU/1/04/279/015 20040706; UK EU/1/04/279/016 20040706; UK EU/1/04/279/017 20040706; UK EU/1/04/279/018 20040706; UK EU/
2008009Lithuania► SubscribePRODUCT NAME: TEMSIROLIMUSUM; REG. NO/DATE: EU/1/07/424/001 20071119
2004 00036Denmark► SubscribePRODUCT NAME: PREGABALIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/04/279/001-025 20040706
0130007 00075Estonia► SubscribePRODUCT NAME: KRISOTINIIB;REG NO/DATE: K(2012)7617 LOPLIK 23.10.2012
155Luxembourg► SubscribePRODUCT NAME: CRIZOTINIB, EVENTUELLEMENT SOUS LA FORME D UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE
C0037France► SubscribePRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001-005 20010313; FIRST REGISTRATION: IKS55243 20000926
438Luxembourg► Subscribe91438, EXPIRES: 20200414
9Finland► Subscribe
154Luxembourg► SubscribePRODUCT NAME: AXITINIB, EVENTUELLEMENT SOUS LA FORME D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Department of Justice
Cantor Fitzgerald
AstraZeneca
Argus Health
Fish and Richardson
Johnson and Johnson
Federal Trade Commission
Chinese Patent Office
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot